

The European Myeloma Network

An overview of the network

History and goals

Important dates

- 2005 creation of the network with a small group
- 2017 new Bylaw of the EMN
- 2019 inclusion of other relevant collaborative groups under the EMN

Our goals

- Perform large, international trials in myeloma and related conditions
- Uniform standards for correlative studies
- Quality control
- Consensus, guidelines and recommendations in Europe
- Platform for analyses and meta-analyses
- Spread knowledge through workshops and meetings



Organization



Young EMN Board (operative)

Dr. Broijl	Dr. Radocha
Dr. Gay	Dr. Krauth
Dr. Popat	Dr. Touzeau
Dr. Gavriatopoulou	Dr. Ocio
Dr. Rasche	Dr. Slordhal
	Dr. Cengiz-Seval

Board of Directors:

Prof. Sonneveld (President)
Prof. Boccadoro (Vice president)
Prof. Dimopoulos (Member)
Prof. Einsele (Member)
Prof. Ludwig (Member)
Prof. San Miguel (Member)
Prof. Cook (Member)
Prof. Hajek (Member)
Prof. Moreau (Member)
Prof. Schjesvold (Member)


Participants:

Open registration to EMN to be included in the projects and trials of the network.

Registration online is required
www.myeloma-europe.org




Organization




President – Vice President – 2 board members (4 years)

- The EB reports to the Board of Directors and prepares actions and proposals, to be approved by the Board.
- The EB is responsible for annual report and meetings. EB members are appointed by the Board.
- This EB will act as main point of contact/interlocutor of the EMN and it will be directly involved in negotiations with third parties

Organogram



Headquarters and data center



Trials

The EMN conducts trials in **myeloma** and other rare hematologic conditions:
smoldering myeloma, amyloidosis, plasma cell leukemia

EMN study code	Main study drug/s	Setting
EMN01	Lenalidomide	Newly diagnosed transplant-ineligible myeloma
EMN02	Bortezomib, Lenalidomide	Newly diagnosed transplant-eligible myeloma
EMN04	Reduced-intensity allogeneic	Relapsed myeloma
EMN07	Carfilzomib, Pomalidomide	Relapsed/Refractory myeloma
EMN09	Carfilzomib, Bendamustine	Relapsed/Refractory myeloma
EMN10	Ixazomib, Bendamustine	Newly diagnosed transplant-ineligible myeloma
EMN11	Carfilzomib, Pomalidomide	Relapsed/Refractory myeloma
EMN12	Carfilzomib, Lenalidomide	Newly diagnosed primary plasma cell leukemia
EMN13	Ixazomib	Relapsed/Refractory myeloma
EMN14	Pomalidomide, Daratumumab	Relapsed/Refractory myeloma
EMN15	Carfilzomib, Lenalidomide	Smoldering myeloma
EMN17	Daratumumab, Bortezomib, Lenalidomide	Newly diagnosed transplant-eligible myeloma
EMN18	Daratumumab, Bortezomib	Newly diagnosed transplant-eligible myeloma
EMN19	Daratumumab, Bortezomib	Extramedullary disease
EMN20	Carfilzomib, Lenalidomide	Newly diagnosed transplant-ineligible myeloma
EMN22	Daratumumab	Newly diagnosed patients with stage 3B light chain AL amyloidosis
EMN23	Retrospective, observational	Patients with systemic AL amyloidosis in Europe
EMN24	Isatuximab, Carfilzomib, Lenalidomide	Newly Diagnosed transplant-eligible myeloma
EMN26	Iberdomide	Phase 2, maintenance therapy
Covid-19	Data collection	Covid-19 MM patients

Protocol Review Committee (scientific & technical) assesses proposals

Many other studies under definition will be available soon



Meetings

Discussion of clinical studies and international events to share knowledge



EMN Trialist Forum

- Annual meeting of the EMN core investigators
- 2-day event in Sept/Oct in Baveno – Italy
- Discussion of practical issues, amendments and new proposals under the EMN umbrella

EMN annual meeting

- A recent, event for all investigators working in the myeloma field
- 3-day event in April; EMN2022 in Amsterdam
- Educational sessions, Meet the Experts, Symposia & 800/1,000 attendees expected



Collaborative projects

EMN: an umbrella organization for collaborative groups and projects



HARMONY

A public-private European Network of Excellence - January 2017

Goal: to harness and mine Big Data to speed up the development of improved treatments.

How: Clinical and translational data are merged together in a big database - 53 partners and 32 associated members from 22 countries, including 8 pharma-companies from EFPIA.



HORIZON 2020 European Commission framework - MMPredict project

Goal: to clinically validate a personalized medicine tool that predicts the most effective treatment option in myeloma patients.

How: SkylineDX is developing a microarray-test that can be used for genetic subtyping of myeloma patients → determine the most suitable treatment for patients by predicting their response based on gene expression profiling.



Publications

Guideline team:

Engelhardt, Terpos, Gay, van de Donk



Main EMN papers in 2020/2021

- Covid-19 vaccines in MM – Lancet Haematol
- Consolidation in EMN02 – Lancet Haematol
- Consolidation & Maintenance in EMN - JCO
- Dara-pom-dex Apollo study – Lancet Oncol
 - Smoldering MM – Haematologica
- MRD in EMN02 – Blood Cancer J
- Vaccination in MM – Leukemia
 - Frailty in MM – Leukemia
- MM Management in Covid-19 pandemic - Leukemia

Abstracts to
congresses

Trial original
papers

Consensus &
recommendations

Review articles



Contacts

The **EMN** staff is pleased to receive any comment, suggestion or proposal.

E-mail addresses:

info@emn.life

datacenter@emn.life

Website: www.myeloma-europe.org

Big objectives can be achieved only through big collaborations

